SECONDARY PREVENTION OF SMALL SUBCORTICAL STROKES (SPS3)

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 皮质下小卒中二级预防(SPS3)项目的总体目标是确定治疗大脑小动脉疾病及其最常见的两种临床表现的有效方法：皮质下小卒中(S3，也称为腔隙卒中)和认知衰退(血管性痴呆)。S3患者的最佳抗血小板治疗和抗高血压治疗可以减少中风复发和认知功能下降，但尚未确定，可能会产生重要的健康益处。主要目的是确定由阿司匹林和氯吡格雷组成的联合抗血小板治疗在减少中风复发、认知功能下降和主要血管事件方面是否优于阿司匹林。此外，为了确定在减少中风复发、认知功能下降和主要血管事件方面，“密集”降压至特定目标范围是否优于“常规”高血压治疗。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall aim of the Secondary Prevention of Small Subcortical Strokes (SPS3) project is to define efficacious therapies for cerebral small artery disease and its two most common clinical manifestations: small subcortical strokes (S3, also called lacunar strokes) and cognitive decline (vascular dementia). Optimal antiplatelet therapy and antihypertensive management of S3 patients to reduce stroke recurrence and cognitive decline has not been defined and is likely to yield important health benefits. Primary aims are to determine whether combination antiplatelet therapy consisting of aspirin plus clopidogrel is superior to aspirin for reducing recurrent stroke, cognitive decline and major vascular events. Also, to determine whether "intensive" blood pressure lowering to a specific target range is superior to "usual" hypertension management for reducing recurrent stroke, cognitive decline and major vascular events.